secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001104659-23-057256
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin Pharma Q1 net loss $2.6M; cash $17M; first patient dosed in Netherton trial
--------------------------------------------------------------------------------

- Net loss $2.6M for Q1 2023 vs $1.7M in Q1 2022; cash & equivalents $17.0M as of March 31, 2023.
- First patient dosed in open-label trial of QRX003 for Netherton Syndrome patients on off-label systemic therapy.
- Recruiting and dosing continue in double-blinded, placebo-controlled study of QRX003 for Netherton Syndrome.
- Completed public offering in Feb 2023 with net proceeds ~$5.8M, extending cash runway into 2H 2024.
- Two rare disease programs with Queensland University of Technology; expect clinical testing in Australia in 2H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465923057256/0001104659-23-057256-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465923057256/tm2314978d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-057256

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer